+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Periodontal Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • PDF Icon

    Report

  • 128 Pages
  • May 2024
  • Region: Global
  • IMARC Group
  • ID: 5970274
The 7 major periodontal disease markets reached a value of US$ 218.3 Million in 2023. Looking forward, the publisher expects the 7MM to reach US$ 329.1 Million by 2034, exhibiting a growth rate (CAGR) of 4.67% during 2023-2034.

The periodontal disease market has been comprehensively analyzed in this report titled "Periodontal Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Periodontal disease refers to a chronic inflammatory condition that affects the gums and supporting structures of the teeth. This illness usually begins with the formation of plaque, a sticky film of bacteria that forms on the teeth. The symptoms of the ailment can vary depending on the stage and severity of the disease, but individuals suffering from the disorder mainly experience swollen, red, and tender gums. Numerous other indications associated with the condition include persistent bad breath, toothache, sensitive teeth, receding gums, painful chewing, bleeding, pocket formation that can trap bacteria and food debris, etc. The diagnosis of periodontal disease involves a combination of clinical examination, medical history assessments, and several other laboratory tests. A healthcare provider will initially examine the gums, teeth, and mouth to check for any signs of bleeding, inflammation, or recession of the gums, which are indicative of the ailment. In some cases, an additional workup may be required to determine the cause of underlying symptoms. This may include imaging procedures, like X-rays, to assess bone levels or dental issues among patients.

The increasing prevalence of dental plaque that can harden into tartar, leading to irritation and inflammation in the gums, is primarily driving the periodontal disease market. Moreover, the rising incidences of various associated risk factors, such as smoking, genetic predisposition, bad oral hygiene, hormonal changes, a weakened immune system, certain systemic diseases, etc., are also bolstering the market growth. In addition to this, the widespread adoption of topical antimicrobial gels containing antibiotics or antiseptics, which can be applied directly to the infected gum pockets to control bacteria and promote healing, is acting as another significant growth-inducing factor. Furthermore, the inflating demand for soft tissue grafts, in which healthy tissue is placed in areas of gum recession to help in covering exposed tooth roots, is also creating a positive outlook for the market. Additionally, the emerging popularity of dental lasers for treating the ailment, since they work by stimulating cellular activity and accelerating the regeneration of gum tissue, leading to quicker recovery times in patients, is expected to drive the periodontal disease market in the coming years.

This report provides an exhaustive analysis of the periodontal disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for periodontal disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the periodontal disease market in any manner.

Time Period of the Study

  • Base Year: 2023
  • Historical Period: 2018-2023
  • Market Forecast: 2024-2034

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan

Analysis Covered Across Each Country

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the periodontal disease market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the periodontal disease market

Competitive Landscape:

This report also provides a detailed analysis of the current periodontal disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

  • How has the periodontal disease market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
  • What was the country-wise size of the periodontal disease market across the seven major markets in 2023 and what will it look like in 2034?
  • What is the growth rate of the periodontal disease market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the market?

Epidemiology Insights

  • What is the number of prevalent cases (2018-2034) of periodontal disease across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of periodontal disease by age across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of periodontal disease by gender across the seven major markets?
  • How many patients are diagnosed (2018-2034) with periodontal disease across the seven major markets?
  • What is the size of the periodontal disease patient pool (2018-2023) across the seven major markets?
  • What would be the forecasted patient pool (2024-2034) across the seven major markets?
  • What are the key factors driving the epidemiological trend of periodontal disease?
  • What will be the growth rate of patients across the seven major markets?

Periodontal Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed drugs and what are their market performance?
  • What are the key pipeline drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed drugs and what are their efficacies?
  • How safe are the late-stage pipeline drugs and what are their efficacies?
  • What are the current treatment guidelines for periodontal disease drugs across the seven major markets?
  • Who are the key companies in the market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the periodontal disease market?
  • What are the key regulatory events related to the periodontal disease market?
  • What is the structure of clinical trial landscape by status related to the periodontal disease market?
  • What is the structure of clinical trial landscape by phase related to the periodontal disease market?
  • What is the structure of clinical trial landscape by route of administration related to the periodontal disease market?
This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.

Table of Contents

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Periodontal Disease - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 Periodontal Disease - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 Patient Journey
7 Periodontal Disease - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 Periodontal Disease - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 Periodontal Disease - Unmet Needs10 Periodontal Disease - Key Endpoints of Treatment
11 Periodontal Disease - Marketed Products
11.1 List of Periodontal Disease Marketed Drugs Across the Top 7 Markets
11.1.1 Arestin (Minocycline controlled-release) - OraPharma
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Atridox (Doxycycline hyclate) - QLT USA
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 Periodontal Disease - Pipeline Drugs
12.1 List of Periodontal Disease Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name - Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. Periodontal Disease - Attribute Analysis of Key Marketed and Pipeline Drugs
14. Periodontal Disease - Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 Periodontal Disease - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Periodontal Disease - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Periodontal Disease - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Periodontal Disease - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Periodontal Disease - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Periodontal Disease - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Periodontal Disease - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Periodontal Disease - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Periodontal Disease - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Periodontal Disease - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Periodontal Disease - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Periodontal Disease - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Periodontal Disease - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Periodontal Disease - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Periodontal Disease - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Periodontal Disease - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Periodontal Disease - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Periodontal Disease - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Periodontal Disease - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Periodontal Disease - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Periodontal Disease - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Periodontal Disease - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Periodontal Disease - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Periodontal Disease - Access and Reimbursement Overview
16 Periodontal Disease - Recent Events and Inputs From Key Opinion Leaders
17 Periodontal Disease Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 Periodontal Disease Market - Strategic Recommendations19 Appendix

Methodology

Loading
LOADING...

Table Information